Boehringer Ingelheim has announced the advancement of BI 3034701, a long-acting, potential first-in-class triple-agonist peptide being developed for the treatment of obesity. The progress marks a key milestone in the company’s strategy to tackle the global burden of obesity and its interlinked cardiovascular, renal, and metabolic (CRM) complications.

Globally, more than one billion people live with obesity—a complex, chronic condition that significantly increases the risk of liver, cardiovascular, renal, and metabolic disorders. Boehringer Ingelheim’s integrated development approach aims to deliver therapies that achieve meaningful outcomes, focusing not only on weight reduction but also on broader health improvements. The company emphasises the importance of interventions that are effective, tolerable, and sustainable for long-term disease management.

The advancement of BI 3034701 follows the successful completion of a randomised, placebo-controlled phase I study involving healthy volunteers and individuals with overweight or obesity. The candidate demonstrated a favourable safety and tolerability profile, along with encouraging early signals of weight loss.

BI 3034701 was originally developed in collaboration with Gubra. Boehringer Ingelheim now holds exclusive responsibility for further development and global commercialisation. The asset’s progression strengthens the company’s expanding patient-focused CRM pipeline and reinforces its ambition to deliver next-generation metabolic therapies.

Boehringer Ingelheim, a global biopharmaceutical company active across human and animal health, is among the industry’s leading research and development investors. Its portfolio is centred on innovative therapies that address areas of significant unmet medical need. Founded in 1885 and remaining independently owned, the company maintains a long-term strategic outlook with sustainability embedded throughout its value chain.